Twist Bioscience's ( TWST ) revenue growth continues to moderate, which is at least partly due to macro headwinds. There are also some temporary factors weighing on growth at the moment. This isn't surprising, as I previously suggested that headwindsRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can be achieved by identifying ...

DENVER, Nov. 17, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that Kraig Biocraft Laboratories’ (OTCQB: KBLB), the undisputed global leader in the development and commercialization of spider silk, execution, including parallel facility cycles and selective breeding advancements, spider silk commercialization program remains on-track. The 2025 production program will soon feature the first large-sc ...

Core Insights - ERS Genomics and Dyadic Applied BioSolutions have entered into a CRISPR/Cas9 license agreement, allowing Dyadic to utilize ERS' extensive patent portfolio to enhance its bioproduction capabilities [1][2][3] Company Overview - ERS Genomics holds a portfolio of over 100 patents worldwide related to CRISPR/Cas9 technology, covering applications across various cell types and synthetic biology [3][6] - Dyadic Applied BioSolutions specializes in producing precision-engineered, animal-free proteins and enzymes for the life sciences, food and nutrition, and bio-industrial markets [5] Agreement Details - The agreement enables Dyadic to integrate CRISPR-based gene editing into its production platforms, specifically the C1 and Dapibus systems, to improve strain performance and product quality [2][3] - Financial details of the agreement have not been disclosed [4] Strategic Implications - The collaboration is expected to accelerate Dyadic's internal product pipeline and enhance the development of customized production strains for partners [2] - ERS Genomics emphasizes the importance of responsible use of CRISPR technology, aiming to support a wide range of applications in life sciences and bio-industrial sectors [2][3]

Core Insights - Beam Therapeutics Inc. is a precision-genetics firm specializing in base editing, focusing on one-time ex vivo and in vivo treatments for hematology and liver genetic diseases [1] Company Overview - Beam Therapeutics is pioneering innovative genetic therapies aimed at providing durable and potentially functional cures for specific genetic disorders [1] Research and Development Focus - The company is dedicated to developing advanced treatments that could significantly impact the management of hematology and liver-related genetic diseases [1]

Core Insights - The article highlights the commercialization of spider silk by Kraig Biocraft Laboratories as a significant advancement in materials science, comparable to the impact of Kevlar in the 1970s [2][4][7] Company Overview - Kraig Biocraft Laboratories (OTCQB: KBLB) is focused on developing and commercializing spider silk-based fiber technologies through a proprietary genetic engineering platform that utilizes silkworms [9] Technological Innovation - The company has successfully used CRISPR-like gene editing to transfer spider DNA into silkworms, creating transgenic silkworms that produce spider silk, which is five times tougher than steel by weight and more flexible than Kevlar [3][4] - The spider silk produced is natural, renewable, biodegradable, and scalable, with production now measured in metric tons [4] Market Potential - Kraig has announced pending commercial sales orders and is actively fulfilling them, including an order from a European luxury fashion house and discussions with a top-tier performance sportswear brand [5][7] - The company is positioned to redefine multiple industries, including high-performance apparel, aerospace composites, and medical applications, with the potential for the first commercial scale sale of mass-produced spider silk [7] Operational Expansion - Kraig Labs is expanding its global footprint with two operational rearing facilities in Southeast Asia and a third location being finalized to meet rising demand [6]

Core Insights - Kraig Biocraft Laboratories, Inc. has significantly increased the production throughput of its recombinant spider silk production platform, marking a major advancement in spider silk technology [1][6]. Company Developments - The increase in production is attributed to the successful selective breeding of parental strains for hybrid silkworms, which form the basis of the recombinant spider silk production system [2][3]. - The first successful hybrid, BAM-1, demonstrated hybrid vigor, leading to increased cocoon shell weight and robustness, which are critical for silk output [2][4]. - The new advanced hybrid, BAM-1 Alpha, has shown a measurable hybrid vigor increase of 22%, representing over a 245% improvement compared to the original BAM-1 [4][5]. Production and Commercialization - The BAM-1 Alpha hybrid is expected to be the primary production strain moving forward, producing larger cocoons and more silk, which will lower production costs [5][6]. - Kraig Labs plans to leverage its multi-facility production infrastructure to integrate BAM-1 Alpha into ongoing manufacturing, supporting its vision of delivering high-performance spider silk fibers for various applications [6][7]. Industry Position - Kraig Labs continues to lead in spider silk research and development, focusing on large-scale commercialization of spider silk technologies [5][7]. - The company's advancements in spider silk technology have significant implications for the global textile industry, with potential applications in performance textiles, defense, medical, and industrial markets [6][10].

Core Insights - Kraig Biocraft Laboratories has achieved a significant milestone in biotechnology by successfully mass-producing spider silk using genetically engineered silkworms, addressing a long-standing challenge in the field [1][4][5] Company Overview - Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) focuses on the development and commercialization of spider silk-based fiber technologies, utilizing a proprietary silkworm-based genetic engineering platform to produce high-performance, cost-effective, and scalable spider silk materials [8] Technological Breakthrough - The company’s genetically engineered silkworms serve as a factory for spider silk production, enabling a scalable and sustainable supply chain that transitions spider silk from laboratory research to practical applications [4][5] Market Potential - The global spider silk market is projected to grow significantly, with forecasts estimating it will reach between $1.3 billion and $1.5 billion by 2035, reflecting a compound annual growth rate (CAGR) of over 30% [6] - This growth is expected to be driven by demand in various sectors, including biomedical applications (sutures, scaffolds, implants), textiles, military uses, and sustainable materials for aerospace and automotive industries [6] Unique Properties of Spider Silk - Spider silk is recognized for its exceptional mechanical properties, including a superior tensile strength-to-weight ratio, outperforming materials like Kevlar and steel [6][7] - Its biocompatibility and biodegradability make it an attractive option for various applications, particularly in biomedical and sustainable material sectors [2][6] Applications and Opportunities - Potential applications for spider silk include stronger and lighter wearables, biodegradable sutures, next-generation body armor, sustainable textiles, and biomimetic actuators in robotics [9]

Core Insights - Kraig Biocraft Laboratories, Inc. has successfully completed its first simultaneous production cycle across two independent rearing centers, marking a significant milestone in its spider silk technology production model [1][4][5] Production Model - The company has implemented a dual-facility production model that enhances throughput and supply chain resilience, establishing a foundation for continuous recombinant spider silk production [1][4] - Each facility operated autonomously while maintaining coordinated scheduling and oversight from the company's production leadership, demonstrating effective logistics and staffing management [2] Production Efficiency - A staggered two-week offset between the start of each cycle allows for seamless integration of outputs, resulting in a continuous supply of finished cocoons and silkworm eggs for subsequent rearing cycles [3] - This synchronized operation eliminates downtime between cycles, creating a robust and scalable production rhythm [3] Strategic Implications - The successful execution of parallel batches validates the scalability of the company's production model and lays the groundwork for significant production expansion planned for the fourth quarter [4] - The dual-facility model enhances supply chain security and substantially increases total throughput capacity, supporting the company's long-term production objectives and meeting growing demand from diverse end-use markets [4][5] Market Position - The completion of the first simultaneous production cycle signals the arrival of a more mature and industrial-scale spider silk manufacturing platform, positioning the company to accelerate growth and enhance efficiency [5]

Core Insights - Kraig Biocraft Laboratories (KBLB) is advancing its recombinant spider silk production program, aiming to deliver initial fiber samples to sports companies, marking a transition from R&D to potential revenue generation [1][4] - The global sports apparel market is projected to reach $400 billion by 2030, driven by innovation and demand for sustainable gear, with premium and technical apparel being the fastest-growing segments [3] - Kraig Labs' entry into the performance and technical sportswear market, valued at $50–70 billion, could create a high-margin niche, leveraging spider silk's advantages over traditional petroleum-based materials [4][8] Company Developments - Kraig Labs plans to begin delivering first-generation spider silk textiles and apparel prototypes in Q4 2025, with feedback from sports companies guiding future product development [6] - The company is focusing on various applications, including compression wear, temperature regulation apparel, and gear for extreme and contact sports [7] - If spider silk apparel captures 0.5–1% of the sports and outdoor apparel market by 2030, it could represent $2–4 billion in annual revenue potential [8] Market Opportunity - The demand for sustainable high-performance apparel aligns with the preferences of eco-conscious athletes and brands, positioning Kraig Labs favorably in the market [5] - The company is refining its Dragon Silk™ technologies and expanding production capabilities to meet anticipated demand [6][14] - Strategic partnerships with technical apparel and sportswear leaders are essential for scaling production and optimizing performance [14]

Core Insights - Kraig Biocraft Laboratories, Inc. is pursuing the acquisition of an additional silkworm rearing center as part of its multi-facility expansion strategy to enhance the production of recombinant spider silk [1][3] Group 1: Company Developments - The company has achieved significant production growth and operational advancements over the last 18 months, particularly under the leadership of Dr. Nirmal Kumar, a leading expert in sericulture [2][4] - Kraig Labs relocated its headquarters to Asia's traditional silk-producing regions, resulting in record production volumes and streamlined processes [2][3] - The company aims to create a production network designed for continuous rearing cycles, greater reliability, and significant capacity increases to meet rising global demand [3][5] Group 2: Leadership and Strategy - Dr. Kumar's expertise is crucial for guiding the buildout and integration of the new facility, ensuring consistency and efficiency in large-scale operations [4] - The company's expansion efforts are aligned with its long-term vision to supply affordable, high-quality spider silk as a sustainable material solution [5]